Osteopontin Undergoes Polymerization in Vivo and Gains Chemotactic Activity for Neutrophils Mediated by Integrin 9 1

Cell-Matrix Frontier Laboratory, Biomedical Research Unit, Hiroshima University, Minamiku, Hiroshima, Japan.
Journal of Biological Chemistry (Impact Factor: 4.57). 02/2011; 286(13):11170-8. DOI: 10.1074/jbc.M110.189258
Source: PubMed


Osteopontin (OPN) is an integrin-binding inflammatory cytokine that undergoes polymerization catalyzed by transglutaminase 2. We have previously reported that polymeric OPN (polyOPN), but not unpolymerized OPN (OPN*), attracts neutrophils in vitro by presenting an acquired binding site for integrin α9β1. Among many in vitro substrates for transglutaminase 2, only a few have evidence for in vivo polymerization and concomitant function. Although polyOPN has been identified in bone and aorta, the in vivo functional significance of polyOPN is unknown. To determine whether OPN polymerization contributes to neutrophil recruitment in vivo, we injected OPN* into the peritoneal space of mice. Polymeric OPN was detected by immunoblotting in the peritoneal wash of mice injected with OPN*, and both intraperitoneal and plasma OPN* levels were higher in mice injected with a polymerization-incompetent mutant, confirming that OPN* polymerizes in vivo. OPN* injection induced neutrophil accumulation, which was significantly less following injection of a mutant OPN that was incapable of polymerization. The importance of in vivo polymerization was further confirmed with cystamine, a transglutaminase inhibitor, which blocked the polymerization and attenuated OPN*-mediated neutrophil recruitment. The thrombin-cleaved N-terminal fragment of OPN, another ligand for α9β1, was not responsible for neutrophil accumulation because a thrombin cleavage-incompetent mutant recruited similar numbers of neutrophils as wild type OPN*. Neutrophil accumulation in response to both wild type and thrombin cleavage-incompetent OPN* was reduced in mice lacking the integrin α9 subunit in leukocytes, indicating that α9β1 is required for polymerization-induced recruitment. We have illustrated a physiological role of molecular polymerization by demonstrating acquired chemotactic properties for OPN.

Full-text preview

Available from:
  • Source
    • "They showed that neural cell proliferation favors soft substrates, neuronal differentiation even softer ones, whereas oligodendrogenesis needed stiffer substrates. This seeming contradiction, that presumably stiffer SB623-ECM exhibits superior neuropoietic properties to those of MSC-ECM, could be resolved if we consider the other consequences of TGM2-crosslinking activity: unmasking cryptic binding sites within ECM molecules for other ECM components and cell-surface receptors, such as integrins [41,42]. Besides, TGM2 deposited in ECM binds with high affinity to heparin sulfate moieties of syndecan-4 [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transplanting mesenchymal stromal cells (MSC) or their derivatives into a neurodegenerative environment is believed to be beneficial due to the trophic support, migratory guidance, immunosuppression, and neurogenic stimuli they provide. SB623, a cell therapy for the treatment of chronic stroke, currently in a clinical trial, is derived from bone marrow MSC using transient transfection with a vector encoding the human Notch1 intracellular domain. This creates a new phenotype, which is effective in experimental stroke, exhibits equal or superior immunosuppressive and angiogenic activity to parental MSC in vitro, and produces extracellular matrix (ECM) that is exceptionally supportive for neural cell growth. The neuropoietic activity of SB623 and parental MSC has not been compared and the SB623-derived neuropoietic mediators have not been identified. SB623 or parental MSC were cocultured with rat embryonic brain cortex cells on cell-derived ECM in a previously characterized quantitative neuropoiesis assay. Changes in expression of rat neural differentiation markers were quantified using rat-specific qRT-PCR. Human mediators were identified using expression profiling, an enzymatic crosslinking activity, and functional interference studies by means of blocking antibodies, biological inhibitors, and siRNA. Cocultures were immunolabeled for pre-synaptic vesicular transporters to assess neuronal specialization. Among 6 MSC/SB623 pairs, SB623 induced expression of rat neural precursor, oligodendrocyte, and astrocyte markers on average 2.6-3 times stronger than did their parental MSC. SB623 expressed significantly higher FGF2, FGF1, and BMP4, and lower FGFR1 and FGFR2 levels; and human FGF1, FGF2, BMPs, and HGF were implicated as neuropoietic mediators. Neural precursors grew faster on SB623- than on MSC-derived ECM. SB623 exhibited higher expression levels and crosslinking activity of tissue transglutaminase (TGM2). TGM2 silencing reduced neural precursor growth on SB623-ECM. SB623 also promoted the induction of GABA-ergic, but not glutamatergic, neurons more effectively than did MSC. These data demonstrate that SB623 cells tend to support neural cell growth more effectively than their parental MSC and identify both soluble and insoluble mediators responsible, at least in part, for enhanced neuropoietic potency of SB623. The neuropoiesis assay is a useful tool for identifying beneficial factors produced by MSC and their derivatives.
    Full-text · Article · Feb 2014 · Stem Cell Research & Therapy
  • Source
    • "The intramolecular structure, RGD (Arg-Gly-Asp), is an unique sequence that improves cell adhesion in proteins. Through the RGD cell adhesion sequence, OPN may interact with important tumor metastasis factors, including integrin, CD44, vascular endothelial growth factor/epidermal growth factor receptor (VEGF/EGFR), matrix metalloproteinases (MMPs), fibronectin (FN), survivin, transforming growth factor (TGF), tumor necrosis factor (TNF) and urokinase-type plasminogen activator (uPA) to promote cell chemotaxis, adhesion and migration (8–17). Budhu et al(18) and Pan et al(19) put forward the theory that OPN was a significant factor in hepatocellular carcinoma metastasis and that it may be a molecular marker of intrahepatic metastasis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to investigate the inhibitory effects of thalidomide in the hepatocellular carcinoma nude mouse model in order to provide new insights into a comprehensive clinical intervention for hepatocellular carcinoma. MHCC97 cells were routinely cultured, passaged and adjusted to a single cell suspension with a concentration of 2×10(7)/ml. Six-week-old, BALB/C male nude mice were anesthetized and fixed in the prone position, then a subcapsular injection of the single cell suspension was administered into the spleen and their abdomens were closed. A laparotomy and left hepatic lobectomy was performed 14 days later and the abdomens were closed once again. Subsequent to the establishment of the hepatocellular carcinoma model, the nude mice were randomly divided into three groups, each consisting of 12 mice. The early intervention group were immediately provided with the post-operative thalidomide intervention, the late intervention group were provided with the post-operative thalidomide intervention one week subsequent to the surgery, and the negative control group were provided with a placebo intervention (0.9% physiological saline). Each intervention was continuously administered once per day for one week. The osteopontin (OPN) content of the liver tumors was detected using immunohistochemistry. The data were analyzed using an analysis of variance (ANOVA) test. There were significant differences in the OPN levels of the tumors among the early intervention, late intervention and negative control groups. Thalidomide may inhibit the generation of OPN and thereby inhibit the infiltration and metastasis of tumors; the immediate use of thalidomide following hepatectomy in the present study may block the invasion and metasis for liver cancer more effectively.
    Full-text · Article · May 2013 · Experimental and therapeutic medicine
  • Source
    • "OPN is highly expressed in chronic inflammatory diseases and possesses chemotactic activity for macrophages and neutrophils [165–167]. Elevated OPN expression in breast, myeloma, and prostate cancers is associated with poor prognosis [168–170]. OPN is secreted by host stromal cells and cancer cells; however, the role of OPN in metastasis is dependent on the site of production. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The multistep process of metastasis is a major hallmark of cancer progression involving the cointeraction and coevolution of the tumor and its microenvironment. In the tumor microenvironment, tumor cells and the surrounding stromal cells aberrantly secrete matricellular proteins, which are a family of nonstructural proteins in the extracellular matrix (ECM) that exert regulatory roles via a variety of molecular mechanisms. Matricellular proteins provide signals that support tumorigenic activities characteristic of the metastastic cascade such as epithelial-to-mesenchymal (EMT) transition, angiogenesis, tumor cell motility, proliferation, invasion, evasion from immune surveillance, and survival of anoikis. Herein, we review the current understanding of the following matricellular proteins and highlight their pivotal and multifacted roles in metastatic progression: angiopoietin-like protein 4 (ANGPTL4), CCN family members cysteine-rich angiogenic inducer 61 (Cyr61/CCN1) and CCN6, osteopontin (OPN), secreted protein acidic and rich in cysteine (SPARC), tenascin C (TNC), and thrombospondin-1 and -2 (TSP1, TSP2). Insights into the signaling mechanisms resulting from the interaction of these matricellular proteins and their respective molecular partner(s), as well as their subsequent contribution to tumor metastasis, are discussed. In addition, emerging evidences of their promising potential as therapeutic options and/or targets in the treatment of cancer are also highlighted.
    Full-text · Article · Feb 2012 · Journal of Oncology
Show more